… with the intracellular catalytic domain of epidermal growth factor receptor (HER1/EGFR)
tyrosine … Erlotinib treatment was generally well tolerated and the most commonly reported side …

… Targeting epidermal growth factor receptors (EGFR) is an … However, the efficacy of these
agents like erlotinib in patients … growth factor receptors (EGFR) is an important treatment …

… growth factor receptor. We conducted a phase I/II trial to evaluate AUY922 and erlotinib …
patients with EGFR-mutant lung cancer and disease progression during erlotinib treatment. …

… growth factor receptor (EGFR) gene experience a partial response when treated with EGFR
tyrosine kinase inhibitors (TKIs) erlotinib … months of the start of the treatment. At least 50% of …

… Erlotinib (Tarceva) is a specific epidermal growth factor … Gefitinib (Iressa) shares with erlotinib
both a common chemical … 2-fold less potent than erlotinib. Clinical studies have resulted in …

… We conducted a randomized, placebo-controlled, double-blind trial to determine whether
the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non–small-cell lung …

… /EGFR, which include epidermal growth factor and transforming growth factor-α (TGF-α), …
after erlotinib treatment. White bar, without erlotinib (control); striped bar, with erlotinib. (Modified …

… In the present study, the number of caspase-3-positive cells was significantly attenuated
by erlotinib treatment in CP-N rats. Similarly, the elevation of the Bax/Bcl-2 ratio in CP-N was …

… The evolution of the epidermal growth factor receptor (EGFR) as a potential target in the
treatment of cancer was described by Mendelsohn in his recent Karnofsky lecture [10]. He has …

… Transforming growth factor beta (TGFbeta) treatment reduced erlotinib sensitivity in … cells
after treatment with 2 ng/ml TGFbeta for 2 weeks. B, TGFbeta induced erlotinib resistance and …